Cargando…
An Innovative PTD-IVT-mRNA Delivery Platform for CAR Immunotherapy of ErbB(+) Solid Tumor Neoplastic Cells
Chimeric antigen receptor (CAR) immunotherapy includes the genetic modification of immune cells to carry such a receptor and, thus, recognize cancer cell surface antigens. Viral transfection is currently the preferred method, but it carries the risk of off-target mutagenicity. Other transfection pla...
Autores principales: | Georgiou-Siafis, Sofia K., Miliotou, Androulla N., Ntenti, Charikleia, Pappas, Ioannis S., Papadopoulou, Lefkothea C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687928/ https://www.ncbi.nlm.nih.gov/pubmed/36359405 http://dx.doi.org/10.3390/biomedicines10112885 |
Ejemplares similares
-
Recruiting In Vitro Transcribed mRNA against Cancer Immunotherapy: A Contemporary Appraisal of the Current Landscape
por: Miliotou, Androulla N., et al.
Publicado: (2023) -
Development of a novel PTD-mediated IVT-mRNA delivery platform for potential protein replacement therapy of metabolic/genetic disorders
por: Miliotou, Androulla N., et al.
Publicado: (2021) -
PTD-mediated delivery of α-globin chain into Κ-562 erythroleukemia cells and α-thalassemic (HBH) patients’ RBCs ex vivo in the frame of Protein Replacement Therapy
por: Miliotou, Androulla N., et al.
Publicado: (2021) -
Protein Transduction Domain-Mediated Delivery of Recombinant Proteins and In Vitro Transcribed mRNAs for Protein Replacement Therapy of Human Severe Genetic Mitochondrial Disorders: The Case of Sco2 Deficiency
por: Miliotou, Androulla N., et al.
Publicado: (2023) -
Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014)